The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sheremet N.L.

Krasnov Research Institute of Eye Diseases

Eliseeva D.D.

Research Center of Neurology

Kalashnikova A.K.

Sechenov First Moscow State Medical University

Zakharova M.N.

Research Center of Neurology

Typical and atypical optic neuritis

Authors:

Sheremet N.L., Eliseeva D.D., Kalashnikova A.K., Zakharova M.N.

More about the authors

Journal: Russian Annals of Ophthalmology. 2023;139(6): 175‑182

DOI: 10.17116/oftalma2023139061175

Read: 4063 times

Download PDF (RU)
Contact the author
Table of contents

TYPICAL AND ATYPICAL OPTIC NEURITIS
TYPICAL AND ATYPICAL OPTIC NEURITIS

To cite this article:

Sheremet NL, Eliseeva DD, Kalashnikova AK, Zakharova MN. Typical and atypical optic neuritis. Russian Annals of Ophthalmology. 2023;139(6):175‑182. (In Russ.)
https://doi.org/10.17116/oftalma2023139061175

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Optic neuritis (ON) is one of the most common neuro-ophthalmic causes of vision loss worldwide. Demyelinating ON can be idiopathic or be one of the symptoms of autoimmune demyelinating diseases of the central nervous system (CNS) such as multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Demographic, clinical and radiological signs of ON in these CNS diseases have differences. In this regard, typical and atypical ON are currently distinguished. Recognizing the clinical features that differentiate typical MS-associated ON from atypical ON in NMOSD and MOGAD is important for choosing the correct disease management and treatment strategy. This review summarizes the data from clinical, laboratory, instrumental methods of management used for the differential diagnosis of optic neuritis.

Keywords:

optic neuritis
MOG-associated disease
neuromyelitis optica spectrum disorder

Authors:

Sheremet N.L.

Krasnov Research Institute of Eye Diseases

Eliseeva D.D.

Research Center of Neurology

Kalashnikova A.K.

Sechenov First Moscow State Medical University

Zakharova M.N.

Research Center of Neurology

Received:

03.08.2023

Accepted:

26.10.2023

Close metadata

References:

  1. Braithwaite T, Subramanian A, Petzold A, Galloway J, Adderley NJ, Mollan SP, Plant GT, Nirantharakumar K, Denniston AK. Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease. JAMA Neurol. 2020;77(12):1514-1523. https://doi.org/10.1001/jamaneurol.2020.3502
  2. Petzold A, Fraser CL, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R, Andris C, Asgari N, Barnett Y, Battistella R, Behbehani R, Berger T, Bikbov MM, Biotti D, Biousse V, Boschi A, Brazdil M, Brezhnev A, Calabresi PA, Cordonnier M, Costello F, Cruz FM, Cunha LP, Daoudi S, Deschamps R, de Seze J, Diem R, Etemadifar M, Flores-Rivera J, Fonseca P, Frederiksen J, Frohman E, Frohman T, Tilikete CF, Fujihara K, Gálvez A, Gouider R, Gracia F, Grigoriadis N, Guajardo JM, Habek M, Hawlina M, Martínez-Lapiscina EH, Hooker J, Hor JY, Howlett W, Huang-Link Y, Idrissova Z, Illes Z, Jancic J, Jindahra P, Karussis D, Kerty E, Kim HJ, Lagrèze W, Leocani L, Levin N, Liskova P, Liu Y, Maiga Y, Marignier R, McGuigan C, Meira D, Merle H, Monteiro MLR, Moodley A, Moura F, Muñoz S, Mustafa S, Nakashima I, Noval S, Oehninger C, Ogun O, Omoti A, Pandit L, Paul F, Rebolleda G, Reddel S, Rejdak K, Rejdak R, Rodriguez-Morales AJ, Rougier MB, Sa MJ, Sanchez-Dalmau B, Saylor D, Shatriah I, Siva A, Stiebel-Kalish H, Szatmary G, Ta L, Tenembaum S, Tran H, Trufanov Y, van Pesch V, Wang AG, Wattjes MP, Willoughby E, Zakaria M, Zvornicanin J, Balcer L, Plant GT. Diagnosis and classification of optic neuritis. Lancet Neurol. 2022;21(12):1120-1134. https://doi.org/10.1016/S1474-4422(22)00200-9
  3. Zhang YX, Qiu W, Guan HZ, Wu LJ, Ding MP. Editorial: Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management. Front Neurol. 2022;13:844155. https://doi.org/10.3389/fneur.2022.844155
  4. De Lott LB, Bennett JL, Costello F. The changing landscape of optic neuritis: a narrative review. J Neurol. 2022;269(1):111-124.  https://doi.org/10.1007/s00415-020-10352-1
  5. Foo R, Yau C, Singhal S, Tow S, Loo JL, Tan K, Milea D. Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore. Asia Pac J Ophthalmol (Phila). 2022;11(2):184-195.  https://doi.org/10.1097/APO.0000000000000513
  6. Gaier ED, Boudreault K, Rizzo JF 3rd, Falardeau J, Cestari DM. Atypical Optic Neuritis. Curr Neurol Neurosci Rep. 2015;15(12):76.  https://doi.org/10.1007/s11910-015-0598-1
  7. Sarkar P, Mehtani A, Gandhi HC, Dubey V, Tembhurde PM, Gupta MK. Atypical optic neuritis: An overview. Indian J Ophthalmol. 2021;69(1):27-35.  https://doi.org/10.4103/ijo.IJO_451_20
  8. Abel A, McClelland C, Lee MS. Critical review: Typical and atypical optic neuritis. Surv Ophthalmol. 2019;64(6):770-779.  https://doi.org/10.1016/j.survophthal.2019.06.001
  9. Margolin E. The swollen optic nerve: an approach to diagnosis and management. Pract Neurol. 2019;19(4):302-309.  https://doi.org/10.1136/practneurol-2018-002057
  10. Lana-Peixoto MA, Talim N. Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes. Biomedicines. 2019;7(2):42.  https://doi.org/10.3390/biomedicines7020042
  11. Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kümpfel T. Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261(1):1-16.  https://doi.org/10.1007/s00415-013-7169-7
  12. Sharma J, Bhatti MT, Danesh-Meyer HV. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein IgG associated disorder: A comprehensive neuro-ophthalmic review. Clin Exp Ophthalmol. 2021;49(2): 186-202.  https://doi.org/10.1111/ceo.13863
  13. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol. 1991;109(12): 1673-1678. https://doi.org/10.1001/archopht.1991.01080120057025
  14. Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology. 2008;115(6):1079-1082.e5.  https://doi.org/10.1016/j.ophtha.2007.08.004
  15. Bennett JL. Optic Neuritis. Continuum (Minneap Minn). 2019;25(5):1236-1264. https://doi.org/10.1212/CON.0000000000000768
  16. Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012;11(2):157-169.  https://doi.org/10.1016/S1474-4422(11)70274-5
  17. Dobson R, Giovannoni G. Multiple sclerosis — a review. Eur J Neurol. 2019;26(1):27-40.  https://doi.org/10.1111/ene.13819
  18. Papp V, Iljicsov A, Rajda C, Magyari M, Koch-Henriksen N, Petersen T, Jakab G, Deme I, Nagy F, Imre P, Lohner Z, Kovács K, Birkás AJ, Köves Á, Rum G, Nagy Z, Kerényi L, Vécsei L, Bencsik K, Jobbágy Z, Diószeghy P, Horváth L, Galántai G, Kasza J, Molnár G, Simó M, Sátori M, Rózsa C, Ács P, Berki T, Lovas G, Komoly S, Illes Z. A population-based epidemiological study of neuromyelitis optica spectrum disorder in Hungary. Eur J Neurol. 2020;27(2):308-317.  https://doi.org/10.1111/ene.14079
  19. Bennett JL, Costello F, Chen JJ, Petzold A, Biousse V, Newman NJ, Galetta SL. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol. 2023;22(1):89-100.  https://doi.org/10.1016/S1474-4422(22)00187-9
  20. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364(9451):2106-2112. https://doi.org/10.1016/S0140-6736(04)17551-X
  21. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473-477.  https://doi.org/10.1084/jem.20050304
  22. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189.  https://doi.org/10.1212/WNL.0000000000001729
  23. Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica. Nat Rev Dis Primers. 2020;6(1):85.  https://doi.org/10.1038/s41572-020-0214-9
  24. Amaral JM, Talim N, Kleinpaul R, Lana-Peixoto MA. Brazilian Committee for Treatment and Research in Multiple Sclerosis. Optic neuritis at disease onset predicts poor visual outcome in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2020;41:102045. https://doi.org/10.1016/j.msard.2020.102045
  25. Yamagami A, Wakakura M, Inoue K, Ishikawa H, Takahashi T, Tanaka K. Clinical Characteristics of Anti-aquaporin 4 Antibody Positive Optic Neuritis in Japan. Neuroophthalmology. 2018;43(2):71-80.  https://doi.org/10.1080/01658107.2018.1520905
  26. Simaniv TO, Kochergin IA, Zakharova MN, Korobko DS, Zaslavsky LG, Zelenova OV, Abramov SI. Clinical and epidemiological aspects of neuromyelitis optic spectrum diseases in the russian population. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2021;121(7):96-103 (In Russ.). https://doi.org/10.17116/jnevro202112107196
  27. Borisow N, Mori M, Kuwabara S, Scheel M, Paul F. Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. Front Neurol. 2018;9:888.  https://doi.org/10.3389/fneur.2018.00888
  28. Filippatou AG, Mukharesh L, Saidha S, Calabresi PA, Sotirchos ES. AQP4-IgG and MOG-IgG Related Optic Neuritis-Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis. Front Neurol. 2020;11:540156. https://doi.org/10.3389/fneur.2020.540156
  29. de Sèze J, Arndt C. Neuropathies optiques inflammatoires récidivantes et neuromyélite optique [Recurrent inflammatory optic neuritis and neuromyelitis optica]. Rev Neurol (Paris). 2010;166(12):966-969.  https://doi.org/10.1016/j.neurol.2010.09.003
  30. Jacob A, McKeon A, Nakashima I, Sato DK, Elsone L, Fujihara K, de Seze J. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2013;84(8):922-930.  https://doi.org/10.1136/jnnp-2012-302310
  31. Gospe SM 3rd, Chen JJ, Bhatti MT. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. Eye (Lond). 2021; 35(3):753-768.  https://doi.org/10.1038/s41433-020-01334-8
  32. Papais-Alvarenga RM, Carellos SC, Alvarenga MP, Holander C, Bichara RP, Thuler LC. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol. 2008;126(1):12-16.  https://doi.org/10.1001/archophthalmol.2007.26
  33. Nakajima H, Hosokawa T, Sugino M, Kimura F, Sugasawa J, Hanafusa T, Takahashi T. Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. BMC Neurol. 2010;10:45. Published 2010 Jun 18.  https://doi.org/10.1186/1471-2377-10-45
  34. Thongmee W, Padungkiatsagul T, Jindahra P, Khongkhatithum C, Thampratankul L, Vanikieti K. Prognostic Factors for Visual Outcomes Following the First Episode of NMOSD-Related Optic Neuritis in Affected Eyes. Clin Ophthalmol. 2020;14:4271-4278. https://doi.org/10.2147/OPTH.S285443.
  35. Fukuda TG, Silva ITF, dos Santos TSS, et al. Clinical and prognostic aspects of patients with the Neuromyelitis Optica Spectrum Disorder (NMOSD) from a cohort in Northeast Brazil. BMC Neurol. 2022;22:95.  https://doi.org/10.1186/s12883-022-02621-5
  36. Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71(3): 324-330.  https://doi.org/10.1001/jamaneurol.2013.5699
  37. Flanagan EP. Neuromyelitis Optica Spectrum Disorder and Other Non-Multiple Sclerosis Central Nervous System Inflammatory Diseases. Continuum (Minneap Minn). 2019;25(3):815-844.  https://doi.org/10.1212/CON.0000000000000742
  38. Peschl P, Schanda K, Zeka B, Given K, Böhm D, Ruprecht K, Saiz A, Lutterotti A, Rostásy K, Höftberger R, Berger T, Macklin W, Lassmann H, Bradl M, Bennett JL, Reindl M. Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J Neuroinflammation. 2017;14(1):208.  https://doi.org/10.1186/s12974-017-0984-5
  39. Waters P, Fadda G, Woodhall M, O’Mahony J, Brown RA, Castro DA, Longoni G, Irani SR, Sun B, Yeh EA, Marrie RA, Arnold DL, Banwell B, Bar-Or A; Canadian Pediatric Demyelinating Disease Network. Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children with Demyelinating Syndromes. JAMA Neurol. 2020;77(1):82-93.  https://doi.org/10.1001/jamaneurol.2019.2940
  40. Jarius S, Metz I, König FB, Ruprecht K, Reindl M, Paul F, Brück W, Wildemann B. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case. Mult Scler. 2016;22(12):1541-1549. https://doi.org/10.1177/1352458515622986
  41. Sechi E, Cacciaguerra L, Chen JJ, Mariotto S, Fadda G, Dinoto A, Lopez-Chiriboga AS, Pittock SJ, Flanagan EP. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front Neurol. 2022;13:885218. https://doi.org/10.3389/fneur.2022.885218
  42. Chen JJ, Flanagan EP, Jitprapaikulsan J, López-Chiriboga ASS, Fryer JP, Leavitt JA, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Tobin WO, Keegan BM, Lucchinetti CF, Kantarci OH, McClelland CM, Lee MS, Bennett JL, Pelak VS, Chen Y, VanStavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Brazis PW, Sagen J, Pittock SJ. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. Am J Ophthalmol. 2018; 195:8-15.  https://doi.org/10.1016/j.ajo.2018.07.020
  43. Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, Lechner-Scott J, Vucic S, Henderson APD, Barnett MH, Reddel SW, Brilot F, Dale RC; Australasian and New Zealand MOG Study Group. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89(2):127-137.  https://doi.org/10.1136/jnnp-2017-316880
  44. Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, Tackley G, Hamid S, Sheard A, Reynolds G, Chandratre S, Hemingway C, Jacob A, Vincent A, Leite MI, Waters P, Palace J. Clinical presentation and prognosis in MOG-antibody disease: a UK study [published correction appears in Brain. 2018;141(4):e31]. Brain. 2017;140(12):3128-3138. https://doi.org/10.1093/brain/awx276
  45. Pröbstel AK, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson NS, Lindberg RL, Kappos L, de Seze J, Derfuss T. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation. 2015;12:46.  https://doi.org/10.1186/s12974-015-0256-1
  46. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Ringelstein M, Trebst C, Winkelmann A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B; in cooperation with the NeuromyelitisOptica Study Group (NEMOSMOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016; 13(1):280.  https://doi.org/10.1186/s12974-016-0718-0
  47. Liu H, Zhou H, Wang J, Sun M, Teng D, Song H, Xu Q, Wei S. The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis. J Neurol Sci. 2019;396:225-231.  https://doi.org/10.1016/j.jns.2018.11.029
  48. Zhao G, Chen Q, Huang Y, Li Z, Sun X, Lu P, Yan S, Wang M, Tian G. Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China. J Neurol. 2018;265(1):33-40.  https://doi.org/10.1007/s00415-017-8651-4
  49. Havla J, Pakeerathan T, Schwake C, Bennett JL, Kleiter I, Felipe-Rucián A, Joachim SC, Lotz-Havla AS, Kümpfel T, Krumbholz M, Wendel EM, Reindl M, Thiels C, Lücke T, Hellwig K, Gold R, Rostasy K, Ayzenberg I. Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well? J Neuroinflammation. 2021;18(1):121.  https://doi.org/10.1186/s12974-021-02160-9
  50. Levy M, Molazadeh N, Bilodeau PA, Vishnevetsky A, Lotan I, Salky R, Anderson M, Romanow G, Lechner-Scott J, Yeh EA, Giovannoni G. Multiple types of relapses in MOG antibody disease. Mult Scler Relat Disord. 2023;72:104613. https://doi.org/10.1016/j.msard.2023.104613
  51. Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, Fryer JP, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Lucchinetti CF, Kunchok A, McClelland CM, Lee MS, Bennett JL, Pelak VS, Van Stavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Lam BL, Moss H, Beres S, Gilbert AL, Shah V, Armstrong G, Heidary G, Cestari DM, Stiebel-Kalish H, Pittock SJ. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020;95(2):e111-e120. https://doi.org/10.1212/WNL.0000000000009758
  52. Höftberger R, Guo Y, Flanagan EP, Lopez-Chiriboga AS, Endmayr V, Hochmeister S, Joldic D, Pittock SJ, Tillema JM, Gorman M, Lassmann H, Lucchinetti CF. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 2020;139(5):875-892.  https://doi.org/10.1007/s00401-020-02132-y
  53. Biotti D, Bonneville F, Tournaire E, Ayrignac X, Dallière CC, Mahieu L, Vignal C, Dulau C, Brochet B, Ruet A, Ouallet JC, Gout O, Heran F, Menjot de Champfleur N, Tourdias T, Deneve M, Labauge P, Deschamps R. Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. J Neurol. 2017;264(10):2173-2175. https://doi.org/10.1007/s00415-017-8615-8
  54. Cortese R, Battaglini M, Prados F, Bianchi A, Haider L, Jacob A, Palace J, Messina S, Paul F, Wuerfel J, Marignier R, Durand-Dubief F, de Medeiros Rimkus C, Callegaro D, Sato DK, Filippi M, Rocca MA, Cacciaguerra L, Rovira A, Sastre-Garriga J, Arrambide G, Liu Y, Duan Y, Gasperini C, Tortorella C, Ruggieri S, Amato MP, Ulivelli M, Groppa S, Grothe M, Llufriu S, Sepulveda M, Lukas C, Bellenberg B, Schneider R, Sowa P, Celius EG, Proebstel AK, Yaldizli Ö, Müller J, Stankoff B, Bodini B, Carmisciano L, Sormani MP, Barkhof F, De Stefano N, Ciccarelli O; MAGNIMS Study Group. Clinical and MRI measures to identify non-acute MOG-antibody disease in adults. Brain. 2023;146(6):2489-2501. https://doi.org/10.1093/brain/awac480
  55. Stavern G, Flanagan EP, Pittock SJ, Fryer J, Bhatti MT, Chen JJ. Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Positive Optic Perineuritis. Neuroophthalmology. 2019;44(1):1-4. Published 2019 May 28.  https://doi.org/10.1080/01658107.2019.1607883
  56. Ambika S, Durgapriyadarshini S, Padmalakshmi K, Noronha V, Arjundas D. Clinical profile, imaging features and short term visual outcomes of Indian optic neuritis patients with and without seromarkers for myelin oligodendrocyte glycoprotein and neuromyelitis optica. Indian J Ophthalmol. 2022;70(1):194-200.  https://doi.org/10.4103/ijo.IJO_887_21
  57. Geng D, Quan C, Li Y. Brain MRI features of Chinese Brain MRI features of Chinese Han patients with MOG-antibody disease. Mult Scler Relat Disord. 2020;43:102167. https://doi.org/10.1016/j.msard.2020.102167.
  58. Saadeh RS, Ramos PA, Algeciras-Schimnich A, Flanagan EP, Pittock SJ, Willrich MA. An Update on Laboratory-Based Diagnostic Biomarkers for Multiple Sclerosis and Beyond. Clin Chem. 2022;68(9):1134-1150. https://doi.org/10.1093/clinchem/hvac061
  59. Hennes EM, Baumann M, Schanda K, Anlar B, Bajer-Kornek B, Blaschek A, Brantner-Inthaler S, Diepold K, Eisenkölbl A, Gotwald T, Kuchukhidze G, Gruber-Sedlmayr U, Häusler M, Höftberger R, Karenfort M, Klein A, Koch J, Kraus V, Lechner C, Leiz S, Leypoldt F, Mader S, Marquard K, Poggenburg I, Pohl D, Pritsch M, Raucherzauner M, Schimmel M, Thiels C, Tibussek D, Vieker S, Zeches C, Berger T, Reindl M, Rostásy K; BIOMARKER Study Group. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology. 2017;89(9):900-908.  https://doi.org/10.1212/WNL.0000000000004312.
  60. Hyun JW, Woodhall MR, Kim SH, Jeong IH, Kong B, Kim G, Kim Y, Park MS, Irani SR, Waters P, Kim HJ. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry. 2017;88(10):811-817.  https://doi.org/10.1136/jnnp-2017-315998
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.